CAI · Caris Life Sciences Inc
United States · RS rating 95 · As of 2026-11-03
| Price | 32.85 USD |
|---|---|
| 1-day change | +2.3% |
| RS rating (overall / 1M / 3M / 12M) | 95 / 79 / 97 / 59 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 66 / 77 / 75 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +250.0% |
| Sales growth Q/Q | +35.1% |
| Distance from 52-week high | +9.1% |
| Market cap (USD) | $5.6B |